drugset
drugset / Trial / NCT01365546

Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery

NCT01365546 ↗

Phase 3 Completed 30 enrolled Octapharma
NaSingle-groupOpen-labelPrevention

Summary

Proportion of surgeries in which the primary endpoint (overall assessment) is classified as success.

Timeline

Start
2011-06
Primary completion
2014-02
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Wilate Protein / enzyme biologic — Intravenous

Indications

No indication recorded.